RADNOR, Pa., Nov. 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:

If you suffered Edwards losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/edwards-lifesciences-corporation?utm_campaign=mei&mktm=r&utm_source=PR&utm_medium=link&utm_campaign=ew&mktm=r 

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com. 

DEFENDANTS' ALLEGED MISCONDUCT:

The complaint alleges that, throughout the Class Period, Defendants provided overwhelmingly positive statements to investors related to the growth of the company's core product, Transcatheter Aortic Valve Replacement ("TAVR"), while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Edwards' TAVR platform. Specifically, Edwards' claims and confidence relied far too heavily on their perceived ability to engage the claimed low-treatment-rate population of patients and an overestimation of the desire for hospitals and other care facilities to continue to utilize and otherwise commit resources to the TAVR procedures over newer, innovative treatment alternatives.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/hnxR1_RnFHI 

THE LEAD PLAINTIFF PROCESS:

Edwards investors may, no later than December 13, 2024, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Edwards investors who have suffered significant losses to contact the firm directly to acquire more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Jonathan Naji, Esq.

(484) 270-1453

280 King of Prussia Road

Radnor, PA 19087

info@ktmc.com 

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edwards-lifesciences-corporation-ew-investors-december-13-2024-filing-deadline-in-securities-class-action---contact-kessler-topaz-meltzer--check-llp-302300361.html

SOURCE Kessler Topaz Meltzer & Check, LLP